arthritis ranged from 0.26 to 0.5%, with an average of 0.36%. A study conducted in both the Northern and Southern parts of China estimated that the prevalence of ankylosing spondylitis was 0.26%. The positive rate of HLA-B27 in patients of ankylosing spondylitis was >90%, while the rate in the general population was only 6-7%. Another survey conducted in 30 000 textile workers in Shanghai showed that the prevalence of systemic lupus erythematosus in males was 70 per 100 000 persons; and in females, the rate was 113 per 100 000 persons. Data from hospitals in Beijing showed that among patients with systemic lupus erythematosus who visited a doctor, those aged 14-39 yrs comprised 70% of the population, and the male to female ratio was 1:13 while the ratio was 1:4 in patients aged between 40 and 59 yrs. An epidemiology investigation of osteoarthritis conducted in 13 451 steel workers in Shanghai showed that the prevalence of symptomatic osteoarthritis was 2.2% and asymptomatic osteoar- thritis was 53%. The prevalence of osteoarthritis was 11, 27 and 62% in the age groups 30-39, 40-49 and 50-59 yrs, respectively. Looking at primary Sjogren's syndrome, an investigation was conducted in 1992 in all adults (total 2060) living in a suburban region of Beijing, including screening with anti-nuclear antibodies (ANA), rheumatoid factor and anti-SSA(Ro)/anti-SSB(La) as well as a questionnaire. For those who were positive in any of the screen tests, additional tests for keratoconjunctivitis sicca and salivary gland involvement were performed. The results showed that the prevalence of primary Sjogren's syndrome in the Beijing area was 0.77% based on the Copenhagen criteria and 0.29% based on the San Diego criteria. Therefore, we concluded that primary Sjogren's syndrome is not a rare disease in China. Recently, another investigation was conducted to explore the current therapeutic strategy for rheumatoid arthritis in China. Eleven regions and 56 hospitals took part in this study. So far, 2202 patients with rheumatoid arthritis have been registered, 436 males and 1766 females, with the average age of 48.66 16.05 (8-90) yrs and mean disease duration of 86.49 98.47 (1-664) months. The involved joints at the onset of disease were hand (61.76%), knee (35.6%), wrist (34.29%), shoulder (18.89%), foot (17.71%), ankle (17.57%), elbow (15.03%), hip (5.00%) and spine (3.95%). The first drug taken by patients was non-steroidal anti- inflammatory drugs (NSAIDs) (53.04%), disease-modifying anti-rheumatic drugs (DMARDs) (21.21%), glucocorticosteroids (16.89%), Chinese traditional medicine (9.49%) and drugs with unknown component (11.99%). The first DMARD prescribed was methotrexate (60.81%), sulphasalazine (22.55%), leflunomide (16.01%), hydroxychloroquine (7.88%) D-penicillamine (7.29%), etc. The average time from joint pain to joint function impair- ment was 36.38 66.63 months, and the time to joint deformity was 55.61 73.87 months. Investigation also revealed that the average time from joint pain to DMARDs prescription in patients without joint deformity was 36.33 68.48 months, while the time was 75.69 98.43 months in patients with joint deformity, suggesting that early prescription of DMARDs could effectively prevent joint destruction. With the development of the Chinese economy and improvement of the living standards of the Chinese people, gout, a formerly rare disease, has become more and more common and been increasingly recognized since the 1990s. An epidemiology survey on gout is underway. It is also noteworthy that with the development of the Chinese economy, government investment on medical research has increased. Chinese medical society becomes more open